Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Gilead Beats Q3 Expectations Fueled by HIV Drug Sales, Raises Full-Year Guidance
Gilead Sciences reported 7% Q3 revenue growth, with $7.5B in earnings surpassing forecasts. The company raised its full-year product sales guidance to $27.8B-$28.1B and adjusted profit forecast to $4.25-$4.45 per share. HIV sales grew 9% to $5.1B, driven by Biktarvy's 13% surge to $3.5B. Gilead plans to file for FDA approval of twice-yearly subcutaneous PrEP lenacapavir by end of 2024, aiming to expand its reach. COVID-19 antiviral Veklury contributed $692M, while oncology drug Trodelvy missed estimates by $8M despite 17% growth. Gilead's CAR-T therapy anito-cel showed a 95% overall response rate in multiple myeloma patients.
Johnson & Johnson MedTech gains FDA approval for Varipulse PFA system
The FDA approval of the Varipulse Platform, integrated with the Carto mapping system, allows electrophysiologists to perform accurate pulsed field ablation (PFA) procedures, potentially reducing procedure time and improving patient outcomes. The platform, previously under Biosense Webster, is now part of Johnson & Johnson MedTech, which aims to enhance its healthcare technology impact under a unified brand.
J&J wins FDA approval for Varipulse PFA system
Johnson & Johnson received FDA approval for its Varipulse pulsed field ablation system, joining Boston Scientific and Medtronic in the U.S. market for atrial fibrillation treatment. Varipulse is designed for drug-resistant, recurrent paroxysmal AFib and integrates with J&J's Carto 3 mapping system. The PFA technology is seen as safer and more efficient than older ablation methods.
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
Rallybio reports Q3 2024 financials, $75.1M cash runway into mid-2026, and CTA approvals for RLYB212 Phase 2 trial, set to initiate screening in 4Q 2024.
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
XOMA Royalty reports Q3 2024 financials: $7.2M income, FDA approval for Zevra’s MIPLYFFA™ (arimoclomol), $15M royalty monetization with Twist Bioscience, $9.9M cash receipts in Q3, $42.3M YTD.
Drug giants display advanced technologies, solutions at CIIE
At the 7th China International Import Expo, Johnson & Johnson launched INVEGA HAFYERA for schizophrenia, Pfizer showcased dermatology solutions, and GSK announced Phase III studies for Bepirovirsen, a potential hepatitis B treatment, and a public welfare project for systemic lupus erythematosus.
Shockwave Medical Shares First Clinical Outcomes Associated With ...
Shockwave Medical announces first clinical outcomes for Shockwave Javelin Peripheral Intravascular Lithotripsy (IVL) Catheter, showing 99% technical acute procedural success rate. The non-balloon-based lithotripsy platform is designed for patients with peripheral artery disease (PAD). Results support FDA clearance, and the device is expected to have a limited market release soon.
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results
Vanda Pharmaceuticals reports Q3 2024 revenue of $47.7 million, up 23% YoY. Financial guidance for 2024 is revised upwards. Fanapt® launch in bipolar I disorder sees new patient starts increase by over 90% YoY. Fanapt® long-acting injectable program to start in Q4 2024. Milsaperidone NDA for schizophrenia and bipolar I disorder expected in early 2025. PONVORY® commercial launch for multiple sclerosis initiated in Q3 2024. PONVORY® IND applications for psoriasis and ulcerative colitis expected in Q4 2024. Tradipitant NDA for motion sickness to be submitted in Q4 2024.
Pharma firms showcase innovative treatment for major diseases at CIIE
At CIIE, Gilead Sciences submits market application for HIV drug lenacapavir, while Organon unveils SJ02, a long-acting FSH for infertility. Pfizer announces China approval for prostate cancer treatment Talazoparib, and Johnson & Johnson's Teclistamab Injection is approved for multiple myeloma.
© Copyright 2025. All Rights Reserved by MedPath